Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.56 |
| ▸ | JAK3 | P52333 | 3/20 | 0.56 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | WEE1 | P30291 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | KARS1 | Q15046 | 3/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
| ▸ | CCNH | P51946 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30086462 | 1.00 | JAK2 (0.56) | JAK2JAK3ACVR1KCNH2WEE1 | |
| SCHEMBL23906266 | 0.92 | JAK2 (0.47) | JAK2JAK3ACVR1KCNH2WEE1 | |
| SCHEMBL30086569 | 0.92 | JAK2 (0.47) | JAK2JAK3ACVR1KCNH2WEE1 | |
| SCHEMBL30086398 | 0.91 | ACVR1 (0.49) | JAK2JAK3ACVR1KCNH2WEE1 | |
| SCHEMBL23906562 | 0.91 | ACVR1 (0.49) | JAK2JAK3ACVR1KCNH2WEE1 | |
| SCHEMBL23906269 | 0.90 | WEE1 (0.45) | JAK2JAK3ACVR1KCNH2WEE1 | |
| SCHEMBL30086504 | 0.90 | WEE1 (0.45) | JAK2JAK3ACVR1KCNH2WEE1 | |
| SCHEMBL25263571 | 0.87 | CAMK2D (0.53) | JAK2JAK3EGFRKARS1CAMK2D | |
| SCHEMBL30086420 | 0.87 | CAMK2D (0.53) | JAK2JAK3EGFRKARS1CAMK2D | |
| SCHEMBL23887589 | 0.87 | JAK2 (0.52) | JAK2JAK3ACVR1KCNH2WEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2021203131-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | JAK2 1187/4885JAK3 1474/4885ACVR1 4/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | JAK2 1187/4885JAK3 1474/4885ACVR1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.